A5090991902- Dermatology and Skin Diseases
- Antimicrobial Peptides and Activities
- Immune Response and Inflammation
- Fungal Infections and Studies
- Clostridium difficile and Clostridium perfringens research
- Allergic Rhinitis and Sensitization
- Toxin Mechanisms and Immunotoxins
- Food Allergy and Anaphylaxis Research
- Cutaneous lymphoproliferative disorders research
Polpharma Biologics (Netherlands)
2024
L'Oreal (United States)
2021
Roche (France)
2021
Staphylococcus aureus causes a broad spectrum of diseases in humans and animals. It is frequently associated with inflammatory skin disorders such as atopic dermatitis, where it aggravates symptoms. Treatment S. aureus-associated infections antibiotics discouraged due to their broad-range deleterious effect on healthy microbiota ability promote the development resistance. Thus, novel aureus-specific antibacterial agents are desirable. We constructed two chimeric cell wall-lytic enzymes,...
Staphylococcus aureus is suspected to fuel disease activity in cutaneous T-cell lymphomas. In this study, we investigate the effect of a recombinant, antibacterial protein, endolysin (XZ.700), on S. skin colonization and malignant activation. We show that strongly inhibits proliferation isolated from lymphoma significantly decreases bacterial cell counts dose-dependent manner. Likewise, ex vivo both healthy lesional by profoundly inhibited endolysin. Moreover, patient-derived induction IFNγ...
Our skin is home to a diverse community of commensal microorganisms integral cutaneous function. However, microbial dysbiosis and barrier perturbation increase the risk local systemic infection. Staphylococcus aureus particularly problematic bacterial pathogen, with high levels antimicrobial resistance direct association poor healing outcome. Innovative approaches are needed selectively kill pathogens, such as S. aureus, without harming resident microbiota. Here we provide important data on...
Atopic dermatitis (AD) is a chronic skin condition affecting an increasing number of children and adults whose quality life impacted by itch pain. It characterized altered epidermal barrier, inflammation, microbiome dysbiosis particularly over-colonization Staphylococcus aureus. The efficacy tolerance cream containing S. aureus-targeting technology (endolysin) was assessed in open-label, two-week study with mild-to-moderate atopic dermatitis. A total 43 patients ranging from 7 months to 57...